In the LEAP‐004, a single‐arm Phase II study (NCT03776136), 103 melanoma patients who previous progression on anti PD‐1/PD‐L1 were enrolled and treated with lenvatinib plus pembrolizumab. This evidence concerns the gene PDCD1 and melanoma.